-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
-
-
-
-
-
-
-
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
-
-
-
-
-
-
-
Tonix Pharma (TNXP) Reports Prelim FY24 Results
-
-
-
-
-
-
-
Tonix Pharma (TNXP) Announces 1:100 Reverse Share Split
-
15,560 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

